INSM Insmed Incorporated

Q3 2025 10-Q

Filed: Oct 30, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Insmed Incorporated (INSM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

• New risk: Commercialization dependency on BRINSUPRI launched Q3 2025 in US with required regulatory approvals outside US
• Most material update: Medicare reimbursement pressure from IRA potential impact on BRINSUPRI pricing and profitability

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$142M

▲ +52.4% YoY▲ +32.5% QoQ

Net Income

-$370M

▼ -67.8% YoY▼ -15.0% QoQ

Net Margin

-260.0%

▼ -2391bp YoY▲ +3953bp QoQ

Source: XBRL data from Insmed Incorporated Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Insmed Incorporated Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Insmed Incorporated

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.